Triiodothyronine implant - Titan Pharmaceuticals

Drug Profile

Triiodothyronine implant - Titan Pharmaceuticals

Alternative Names: T3 implant - Titan Pharmaceuticals

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Titan Pharmaceuticals
  • Class Amino acids; Small molecules; Thyronines
  • Mechanism of Action Thyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypothyroidism

Most Recent Events

  • 23 Jan 2017 Preclinical trials in Hypothyroidism in USA (SC) (Titan Pharmaceuticals pipeline, January 2017)
  • 16 Nov 2015 Early research in Hypothyroidism in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top